Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMNQG24)

Drug Name

Volociximab Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Non-small-cell lung cancer	2C25.Y	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Integrin alpha-5/beta-1 (ITGA5/B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ATN-161	DM4T9RS	Renal cell carcinoma	2C90	Phase 2	[3]
AMEP	DMFELMQ	Melanoma	2C30	Phase 1	[4]
F-200	DMVWZN1	Ocular disease	1F00.1Z	Terminated	[5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT00369395) A Study of Volociximab in Metastatic Melanoma. U.S. National Institutes of Health.
2	Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent. J Exp Ther Oncol. 2006;5(4):273-86.
3	A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol Cancer Ther. 2006 Sep;5(9):2271-80.
4	Gene electrotransfer of plasmid AMEP, an integrin-targeted therapy, has antitumor and antiangiogenic action in murine B16 melanoma.Gene Ther.2015 Jul;22(7):578-90.
5	US patent application no. 8,541,413, Sustained release eye drop formulations.